|
|
|
|
Name |
Micafungin |
Molecular Formula |
|
Molecular Weight |
1270.28 |
CAS |
235114-32-6 |
Price |
US$990/100mg |
Systematic Name |
|
Certificate of analysis |
|
View via PDF file |
|
Specification |
|
|
White to off-white powder
|
|
Solubility |
Freely soluble in DMSO and methanol |
Conforms |
Identification |
A:The HPLC RT should correspond to that of reference standard.
B:IR And UV correspond to the related rule |
Conforms |
Water |
1.6%-3.0% |
1.8% |
Single impurities |
≤3.0% |
1.7% |
Total impurities |
≤5.0% |
1.2% |
Heavy metals |
≤20mg/L |
Conforms |
|
|
|
|
Should be stored at a temperature below -20℃ |
Contact us for more information
|
|
PD1 |
Products protected by valid patents are not offered for sale in jurisdictions where the sale of such products constitutes a patent infringement. The current list only reflects the products and technologies that are available, under development: note that some products may be developed or produced for internal and experimental uses with no commercal aim. |
PD2 |
Sales of products are limited to those allowed by Chapter VII PLPRC 63, the above includes Research and development quantities. |
PD3 |
the buyer assumes responsibility of all patent considerations in the use of
Lano ’s Pharmaceutical Co.,Ltd's Micafungin,235114-32-6 |
PD4 |
R&D use in accordance with (1) 35 USC 271(e)+A13(1) in the U.S.; (2) Section 69.1 of Japanese Patent Law in Japan; (3) Section 11, No. 2 of the German Patent Act of 1981 in Germany; (iv) Section 60, Paragraph 5b of the U.K. Patents Act of 1977 in the U.K.; (4) Sections 55.2(1) and 55.2(6) and other common law exemptions of Canadian patent law; (5) Section 68B of the Patents Act of 1953 in New Zealand together with the amendment of same by the Statutes Amendment Bill of 2002; (6) such related legislation and/or case law as may be or become applicable in the aforementioned countries; and (7) such similar laws and rules as may apply in various other countries.
|
|
